<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216849</url>
  </required_header>
  <id_info>
    <org_study_id>DFSC-2019(CR)-06</org_study_id>
    <nct_id>NCT04216849</nct_id>
  </id_info>
  <brief_title>Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy</brief_title>
  <official_title>Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a 96-week multicenter, randomized, double-blind, placebo-controlled trial that
      included 3 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 64
      weeks of follow-up.To observe the efficacy and safety of umbilical cord mesenchymal stem cell
      infusion in Chinese patients with type 2 diabetic nephropathy who received traditional
      hypoglycemic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was a 96-week multicenter, randomized, double-blind, placebo-controlled trial that
      included 3 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 64
      weeks of follow-up.We plan to recruit 54 subjects，which were divided into experimental group
      and control group. The volunteers of the experimental group will be given peripheral
      intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cell (HUC-MSC) at
      0,8,16,24,32 week. The control group will be given the same dose of saline. Then
      centralization visit was conducted every 12 weeks until the 96th week.The primary end points
      include estimated glomerular filtration rate and urinary albumin creatinine ratio(UACR). The
      secondary end points include HbA1C,plasma insulin and C-peptide, and insulin dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>96weeks after treatment</time_frame>
    <description>estimated glomerular filtration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UACR</measure>
    <time_frame>96weeks after treatment</time_frame>
    <description>urinary albumin creatinine ratio</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Type 2 Diabetes With Renal Manifestations</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will be given the same dose of saline containing human albumin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <description>human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>saline containing human albumin will be infused to the control group</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  7.5%≤HbA1C≤10%

          -  UACR≥30mg/g creatinine

          -  30mL/min/1.73m^2≤eGFR &lt;60/milliliter/1.73m^2

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  tumor history

          -  Other causes of chronic kidney disease

          -  Abnormal liver function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongming Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital, Shanghai Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Congrong Wang, MD</last_name>
    <phone>+86-021-38804518</phone>
    <email>wcr601@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhongming Liu, MD</last_name>
    <phone>+86-021-38804518</phone>
    <email>liu.zhongmin@tongji.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200124</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Congrong Wang, MD</last_name>
      <phone>+86-021-38804518</phone>
      <email>wcr601@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human umbilical cord mesenchymal stem cells</keyword>
  <keyword>type 2 diabetic nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

